Latest & greatest articles for azithromycin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on azithromycin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on azithromycin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for azithromycin

41. Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial.

Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial. 20442386 2010 05 05 2010 05 06 2016 10 17 1538-3598 303 17 2010 May 05 JAMA JAMA Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial. 1707-15 10.1001/jama.2010.563 Azithromycin is recommended as therapy for cystic fibrosis (CF) patients with chronic (...) Pseudomonas aeruginosa infection, but there has not been sufficient evidence to support the benefit of azithromycin in other patients with CF. To determine if azithromycin treatment improves lung function and reduces pulmonary exacerbations in pediatric CF patients uninfected with P. aeruginosa. A multicenter, randomized, double-blind placebo-controlled trial was conducted from February 2007 to July 2009 at 40 CF care centers in the United States and Canada. Of the 324 participants screened, 260 were

JAMA2010

42. The effect of azithromycin and Chlamydophilia pneumonia infection on expansion of small abdominal aortic aneurysms--a prospective randomized double-blind trial

The effect of azithromycin and Chlamydophilia pneumonia infection on expansion of small abdominal aortic aneurysms--a prospective randomized double-blind trial 19563951 2009 06 30 2009 07 09 2016 11 25 1097-6809 50 1 2009 Jul Journal of vascular surgery J. Vasc. Surg. The effect of azithromycin and Chlamydophilia pneumonia infection on expansion of small abdominal aortic aneurysms--a prospective randomized double-blind trial. 23-9 10.1016/j.jvs.2008.12.048 The aim of the study was to evaluate (...) the effect of azithromycin on the expansion rate of small abdominal aortic aneurysms (AAAs), and to determine whether or not a correlation exists between serological markers for Chlamydophilia pneumonia (Cpn) infection and AAA expansion. Nine vascular centers were included and 259 patients were invited to participate. Ten patients declined and 2 patients had chronic kidney failure, leaving a total of 247 patients. Inclusion criteria were: AAA 35-49 mm and age <80 years. Patients were randomized

EvidenceUpdates2009

43. Effects of prolonged use of azithromycin in patients with cystic fibrosis: a meta-analysis

Effects of prolonged use of azithromycin in patients with cystic fibrosis: a meta-analysis Effects of prolonged use of azithromycin in patients with cystic fibrosis: a meta-analysis Effects of prolonged use of azithromycin in patients with cystic fibrosis: a meta-analysis Florescu DF, Murphy PJ, Kalil AC CRD summary This review found that azithromycin improved lung function in patients with cystic fibrosis, especially those colonised by Pseudomonas . Nausea and diarrhoea were more frequent (...) with azithromycin. The small number of studies, possibility of missed studies and lack of details of the review process made the reliability of the authors' conclusions unclear. Authors' objectives To investigate the efficacy and safety of azithromycin in patients with cystic fibrosis. Searching PubMed and Cochrane Central Register of Controlled Trials (CENTRAL) were searched without language restrictions from inception to April 2008. Search terms were reported. Study selection Randomised controlled trials

DARE.2009

44. Azithromycin-containing versus standard triple therapy for Helicobacter pylori eradication: a meta-analysis

Azithromycin-containing versus standard triple therapy for Helicobacter pylori eradication: a meta-analysis Azithromycin-containing versus standard triple therapy for Helicobacter pylori eradication: a meta-analysis Azithromycin-containing versus standard triple therapy for Helicobacter pylori eradication: a meta-analysis Dong J, Yu XF, Zou J CRD summary The review concluded that azithromycin-containing triple therapy for first-line Helicobacter pylori eradication was equally effective (...) to standard triple eradication therapy and had a lower occurrence of side effects. In view of some potential limitations arising from the review process, and the overall average quality of included trials, the extent to which the authors’ conclusions are reliable is unclear. Authors' objectives To evaluate the safety and effectiveness of the addition of azithromycin to first-line Helicobacter pylori eradication regimes. Searching PubMed (from 1966), EMBASE (from 1980), Cochrane Central Register

DARE.2009

45. Effect of mass distribution of azithromycin for trachoma control on overall mortality in Ethiopian children: a randomized trial.

Effect of mass distribution of azithromycin for trachoma control on overall mortality in Ethiopian children: a randomized trial. 19724043 2009 09 02 2009 09 04 2016 10 17 1538-3598 302 9 2009 Sep 02 JAMA JAMA Effect of mass distribution of azithromycin for trachoma control on overall mortality in Ethiopian children: a randomized trial. 962-8 10.1001/jama.2009.1266 Mass oral azithromycin distribution to affected communities is a cornerstone of the World Health Organization's trachoma elimination (...) program. Antibiotics are provided to target the ocular strains of chlamydia that cause trachoma, but may also be efficacious against respiratory disease, diarrhea, and malaria--frequent causes of childhood mortality in trachoma-endemic areas. To compare mortality rates of participants aged 1 to 9 years in treated communities with those in untreated communities. We conducted a cluster-randomized clinical trial of mass azithromycin administration for trachoma control. Forty-eight communities (known

JAMA2009

46. Is the frequency of recurrent chest infections, in children with chronic neurological problems, reduced by prophylactic azithromycin?

Is the frequency of recurrent chest infections, in children with chronic neurological problems, reduced by prophylactic azithromycin? BestBets: Is the frequency of recurrent chest infections, in children with chronic neurological problems, reduced by prophylactic azithromycin? Is the frequency of recurrent chest infections, in children with chronic neurological problems, reduced by prophylactic azithromycin? Report By: Charlotte B Kirk - Specialist Registrar in Paediatrics Search checked by Bob (...) Phillips - Section Editor, Archimedes Institution: Royal Hospital for Sick Children, Edinburgh, UK Date Submitted: 29th April 2008 Date Completed: 30th April 2008 Last Modified: 30th April 2008 Status: Green (complete) Three Part Question Do [children with chronic lung disease (not bronchopulmonary dysplasia) and/or bronchiectasis] who are [prescribed long-term azithromycin as prophylaxis] have a [reduction in frequency of respiratory exacerbations without a change in the bacterial flora found

BestBETS2008

47. Azithromycin for acute lower respiratory tract infections.

Azithromycin for acute lower respiratory tract infections. BACKGROUND: Acute lower respiratory tract infections (LRTI) range from acute bronchitis and acute exacerbations of chronic bronchitis to pneumonia. Approximately five million people die of acute respiratory tract infections annually. Among these, pneumonia represents the most frequent cause of mortality, hospitalization and medical consultation. Azithromycin is a new macrolide antibiotic, structurally modified from erythromycin (...) and noted for its activity against some gram-negative organisms associated with respiratory tract infections, particularly Haemophilus influenzae (H. influenzae). OBJECTIVES: To compare the effectiveness of azithromycin to amoxycillin or amoxycillin/clavulanic acid (amoxyclav) in the treatment of LRTI, in terms of clinical failure, incidence of adverse events and microbial eradication. SEARCH STRATEGY: We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library 2007

Cochrane2008

48. Single-dose azithromycin versus erythromycin or amoxicillin for Chlamydia trachomatis infection during pregnancy: a meta-analysis of randomised controlled trials

Single-dose azithromycin versus erythromycin or amoxicillin for Chlamydia trachomatis infection during pregnancy: a meta-analysis of randomised controlled trials Single-dose azithromycin versus erythromycin or amoxicillin for Chlamydia trachomatis infection during pregnancy: a meta-analysis of randomised controlled trials Single-dose azithromycin versus erythromycin or amoxicillin for Chlamydia trachomatis infection during pregnancy: a meta-analysis of randomised controlled trials Pitsouni E (...) , Iavazzo C, Athanasiou S, Falagas M E CRD summary The authors conclude that azithromycin is as effective as erythromycin or amoxicillin for treating Chlamydia trachomatis in pregnancy and has fewer adverse effects. Although the data appear to support these conclusions, they should be interpreted with some caution given the limitations in the search and failure to adequately address inconsistencies between the primary studies. Authors' objectives To assess the effectiveness and safety of azithromycin

DARE.2007

49. Azithromycin for the secondary prevention of coronary artery disease: a meta-analysis

Azithromycin for the secondary prevention of coronary artery disease: a meta-analysis Azithromycin for the secondary prevention of coronary artery disease: a meta-analysis Azithromycin for the secondary prevention of coronary artery disease: a meta-analysis Baker W L, Couch K A CRD summary The authors’ cautious conclusion that azithromycin does not appear to reduce the frequency or occurrence of cardiac events in patients with coronary artery disease appears to reflect the results reported (...) . However, it is possible that relevant studies might have been missed. Authors' objectives To evaluate the effect of the macrolide antimicrobial azithromycin on clinical outcomes in patients with coronary artery disease (CAD). Searching MEDLINE (1966 to September 2006), EMBASE (1990 to September 2006), Web of Science (1994 to September 2006) and the Cochrane Database of Systematic Reviews (Issue 3, 2006) were searched; the search terms were reported. The references of all retrieved articles were also

DARE.2007

50. Effect of azithromycin and clarithromycin therapy on pharyngeal carriage of macrolide-resistant streptococci in healthy volunteers: a randomised, double-blind, placebo-controlled study.

Effect of azithromycin and clarithromycin therapy on pharyngeal carriage of macrolide-resistant streptococci in healthy volunteers: a randomised, double-blind, placebo-controlled study. 17292768 2007 02 12 2007 02 20 2015 06 16 1474-547X 369 9560 2007 Feb 10 Lancet (London, England) Lancet Effect of azithromycin and clarithromycin therapy on pharyngeal carriage of macrolide-resistant streptococci in healthy volunteers: a randomised, double-blind, placebo-controlled study. 482-90 Resistance (...) to antibiotics is a major public-health problem, and studies that link antibiotic use and resistance have shown an association but not a causal effect. We used the macrolides azithromycin and clarithromycin to investigate the direct effect of antibiotic exposure on resistance in the oral streptococcal flora of healthy volunteers. Volunteers were treated with azithromycin (n=74), clarithromycin (74), or placebo (76) in a randomised, double-blind trial. Pharyngeal swabs were obtained before and after

Lancet2007

51. A single dose of azithromycin was more effective than ciprofloxacin for severe cholera in men in Bangladesh

A single dose of azithromycin was more effective than ciprofloxacin for severe cholera in men in Bangladesh A single dose of azithromycin was more effective than ciprofloxacin for severe cholera in men in Bangladesh | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search (...) for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here A single dose of azithromycin was more effective than ciprofloxacin for severe cholera in men in Bangladesh Article Text Therapeutics A single dose of azithromycin was more effective than ciprofloxacin for severe cholera in men in Bangladesh Statistics from Altmetric.com No Altmetric data available

Evidence-Based Medicine (Requires free registration)2006

52. Single-dose azithromycin for the treatment of cholera in adults.

Single-dose azithromycin for the treatment of cholera in adults. 16760445 2006 06 08 2006 06 13 2013 11 21 1533-4406 354 23 2006 Jun 08 The New England journal of medicine N. Engl. J. Med. Single-dose azithromycin for the treatment of cholera in adults. 2452-62 Single-dose azithromycin is effective in the treatment of severe cholera in children, but its effectiveness in adults has not been evaluated. We conducted a double-blind, randomized trial comparing the equivalence of azithromycin (...) and ciprofloxacin (each given in a single 1-g dose of two 500-mg tablets) among 195 men with severe cholera caused by Vibrio cholerae O1 or O139. Patients were hospitalized for five days. A stool culture was performed daily. Primary outcome measures were clinical success (the cessation of watery stools within 48 hours after drug administration) and bacteriologic success (the inability to isolate V. cholerae after 48 hours). Therapy was clinically successful in 71 of 97 patients receiving azithromycin (73

NEJM2006

53. Higher dosages of azithromycin are more effective in treatment of group A streptococcal tonsillopharyngitis

Higher dosages of azithromycin are more effective in treatment of group A streptococcal tonsillopharyngitis Higher dosages of azithromycin are more effective in treatment of group A streptococcal tonsillopharyngitis Higher dosages of azithromycin are more effective in treatment of group A streptococcal tonsillopharyngitis Casey J R, Pichichero M E CRD summary This review determined the optimal dose of azithromycin for treatment of group A streptococcal (GAS) tonsillopharyngitis. The authors (...) concluded that 60 mg/kg azithromycin in children or 3 days of 500 mg/day azithromycin in adults increase GAS eradication and clinical cure. Differences between paediatric studies and inadequate evidence supporting 3-day regimens in adults mean that the authors' conclusions are of doubtful reliability. Authors' objectives To determine the optimal dose of azithromycin for the treatment of group A streptococcal (GAS) tonsillopharyngitis in children and adults. Searching MEDLINE (1966 through 2004

DARE.2005

54. Single-dose azithromycin versus penicillin G benzathine for the treatment of early syphilis.

Single-dose azithromycin versus penicillin G benzathine for the treatment of early syphilis. 16177249 2005 09 22 2005 09 27 2013 11 21 1533-4406 353 12 2005 Sep 22 The New England journal of medicine N. Engl. J. Med. Single-dose azithromycin versus penicillin G benzathine for the treatment of early syphilis. 1236-44 Pilot studies suggest that a single, 2-g oral dose of azithromycin may be an alternative to a 2.4-MU intramuscular dose of penicillin G benzathine in the prevention and treatment (...) of syphilis. We evaluated the efficacy of treatment with azithromycin in a developing country. A total of 328 subjects, 25 with primary and 303 with high-titer (a titer of at least 1:8 on a rapid plasmin reagin [RPR] test) latent syphilis, were recruited through screening of high-risk populations in Mbeya, Tanzania, and randomly assigned to receive 2 g of azithromycin orally (163 subjects) or 2.4 million units of penicillin G benzathine intramuscularly (165 subjects). The primary outcome was treatment

NEJM2005

55. Azithromycin for the secondary prevention of coronary events.

Azithromycin for the secondary prevention of coronary events. 15843666 2005 04 21 2005 05 02 2006 11 15 1533-4406 352 16 2005 Apr 21 The New England journal of medicine N. Engl. J. Med. Azithromycin for the secondary prevention of coronary events. 1637-45 Epidemiologic, laboratory, animal, and clinical studies suggest that there is an association between Chlamydia pneumoniae infection and atherogenesis. We evaluated the efficacy of one year of azithromycin treatment for the secondary prevention (...) of coronary events. In this randomized, prospective trial, we assigned 4012 patients with documented stable coronary artery disease to receive either 600 mg of azithromycin or placebo weekly for one year. The participants were followed for a mean of 3.9 years at 28 clinical centers throughout the United States. The primary end point, a composite of death due to coronary heart disease, nonfatal myocardial infarction, coronary revascularization, or hospitalization for unstable angina, occurred in 446

NEJM2005

56. Mass treatment with single-dose azithromycin for trachoma.

Mass treatment with single-dose azithromycin for trachoma. BACKGROUND: Trachoma, caused by repeated ocular infection with Chlamydia trachomatis, is an important cause of blindness. Current recommended dosing intervals for mass azithromycin treatment for trachoma are based on a mathematical model. METHODS: We collected conjunctival swabs for quantitative polymerase-chain-reaction assay of C. trachomatis before and 2, 6, 12, 18, and 24 months after mass treatment with azithromycin in a Tanzanian (...) community in which trachoma was endemic. For ethical reasons, at 6, 12, and 18 months, we gave tetracycline eye ointment to residents who had clinically active trachoma. RESULTS: At baseline, 956 of 978 residents (97.8 percent) received either one oral dose of azithromycin or (if azithromycin was contraindicated) a course of tetracycline eye ointment. The prevalence of infection fell from 9.5 percent before mass treatment to 2.1 percent at 2 months and 0.1 percent at 24 months. The quantitative burden

NEJM2004

57. Targeted mass treatment for syphilis with oral azithromycin.

Targeted mass treatment for syphilis with oral azithromycin. From mid 1997 to end of 1999, there was a sexually-transmitted infectious syphilis outbreak mainly in heterosexual people in British Columbia, Canada, that was concentrated in Vancouver. The rate across the province increased from less than 0.5 to 3.4 per 100000, and the rate in Vancouver reached 12.9 per 100000. We aimed to eliminate the syphillis outbreak by treating people at risk of infection. In 2000, a targeted mass treatment (...) programme provided azithromycin (1.8 g orally) to 4384 at-risk residents in this city. After the programme, syphilis frequency fell significantly for 6 months (p=0.016), but rose again in 2001. Results from curve fitting analyses showed that the number of cases in 2001 (177) was higher than expected (0.0001<p<0.0044). This rate rebound and the absence of a sustained effect suggest that targeted mass treatment for syphilis, even though feasible, should not be done routinely.

Lancet2003

58. Pharmacoeconomic aspects of antibacterial therapy with azithromycin of community-acquired pneumonia in servicemen

Pharmacoeconomic aspects of antibacterial therapy with azithromycin of community-acquired pneumonia in servicemen Pharmacoeconomic aspects of antibacterial therapy with azithromycin of community-acquired pneumonia in servicemen Pharmacoeconomic aspects of antibacterial therapy with azithromycin of community-acquired pneumonia in servicemen Dzyublyk O Y, Mukhin O O, Simonov S S Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED (...) . Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of oral azithromycin (Sumamed PLIVA, Croatia) in the treatment of community-acquired pneumonia (CAP) was examined. The drug regimen was 500 mg given orally once daily for 3 days. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population The study

NHS Economic Evaluation Database.2003

59. Effect of short-term treatment with azithromycin on recurrent ischaemic events in patients with acute coronary syndrome in the Azithromycin in Acute Coronary Syndrome (AZACS) trial: a randomised controlled trial.

Effect of short-term treatment with azithromycin on recurrent ischaemic events in patients with acute coronary syndrome in the Azithromycin in Acute Coronary Syndrome (AZACS) trial: a randomised controlled trial. 12642046 2003 03 18 2003 04 04 2015 06 16 0140-6736 361 9360 2003 Mar 08 Lancet (London, England) Lancet Effect of short-term treatment with azithromycin on recurrent ischaemic events in patients with acute coronary syndrome in the Azithromycin in Acute Coronary Syndrome (AZACS) trial (...) : a randomised controlled trial. 809-13 There is serological and epidemiological evidence of an association between Chlamydia pneumoniae infection and coronary artery disease. Results of previous smaller studies have indicated a reduction of recurrent ischaemic events in patients with acute coronary syndrome when given macrolide antibiotics. We aimed to assess whether short-term treatment with the macrolide antibiotic azithromycin reduces recurrent ischaemic events in patients admitted for unstable angina

Lancet2003

60. Azithromycin for the secondary prevention of coronary heart disease events: the WIZARD study: a randomized controlled trial.

Azithromycin for the secondary prevention of coronary heart disease events: the WIZARD study: a randomized controlled trial. 13129985 2003 09 17 2003 09 25 2016 10 17 1538-3598 290 11 2003 Sep 17 JAMA JAMA Azithromycin for the secondary prevention of coronary heart disease events: the WIZARD study: a randomized controlled trial. 1459-66 Several lines of evidence have implied an association between Chlamydia pneumoniae infection and atherogenesis. To determine the effect of 12 weeks (...) azithromycin (600 mg/d for 3 days during week 1, then 600 mg/wk during weeks 2-12; n = 3879) or placebo (n = 3868). The primary event was the first occurrence of death from any cause, nonfatal reinfarction, coronary revascularization, or hospitalization for angina. Patients were followed up until 1038 events accrued. After a median of 14 months of follow-up, there was no significant risk reduction in the likelihood of a primary event with azithromycin vs placebo (7% [95% confidence interval, -5% to 17%], P

JAMA2003